Literature DB >> 1683980

Chirality in antirheumatic drugs.

W F Kean1, C J Lock, H E Howard-Lock.   

Abstract

Use of chiral molecules in clinical practice may cause problems because different chiral forms of a drug (enantiomers) may have different biological activities--yet clinicians have little awareness of these risks. After discussion of the chemical conventions used to describe chirality, examples of the influence of chirality on the efficacy and toxicity of antirheumatic drugs are given. It is recommended that single enantiomers should be used in biological experiments and clinical trials.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1683980     DOI： 10.1016/0140-6736(91)92382-c

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  9 in total

1.  Recognition of D-Penicillamine Using Schiff Base Centered Fluorescent Organic Nanoparticles and Application to Medicine Analysis.

Authors:  Prasad G Mahajan; Govind B Kolekar; Shivajirao R Patil
Journal:  J Fluoresc       Date:  2017-01-14       Impact factor: 2.217

2.  The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice.

Authors:  Amanda S Peretti; Dayna Dominguez; Martha M Grimes; Helen J Hathaway; Eric R Prossnitz; Melanie R Rivera; Angela Wandinger-Ness; Donna F Kusewitt; Laurie G Hudson
Journal:  Am J Pathol       Date:  2017-11-21       Impact factor: 4.307

Review 3.  Articular pharmacokinetics of protein-bound antirheumatic agents.

Authors:  P A Simkin; M P Wu; D M Foster
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

4.  Flurbiprofen, S(+), eyedrops: formulation, enantiomeric assay, shelf-life and pharmacology.

Authors:  A A van Sorge; P H Wijnen; J L van Delft; V M Coré-Bodelier; N J van Haeringen
Journal:  Pharm World Sci       Date:  1999-04

Review 5.  Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

Authors:  A K Scott
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

6.  Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro.

Authors:  M Villanueva; R Heckenberger; H Strobach; M Palmér; K Schrör
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 7.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

8.  Homochirality in biomineral suprastructures induced by assembly of single-enantiomer amino acids from a nonracemic mixture.

Authors:  Wenge Jiang; Dimitra Athanasiadou; Shaodong Zhang; Raffaella Demichelis; Katarzyna B Koziara; Paolo Raiteri; Valentin Nelea; Wenbo Mi; Jun-An Ma; Julian D Gale; Marc D McKee
Journal:  Nat Commun       Date:  2019-05-24       Impact factor: 14.919

9.  Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.

Authors:  Tudor I Oprea; Larry A Sklar; Jacob O Agola; Yuna Guo; Melina Silberberg; Joshua Roxby; Anna Vestling; Elsa Romero; Zurab Surviladze; Cristina Murray-Krezan; Anna Waller; Oleg Ursu; Laurie G Hudson; Angela Wandinger-Ness
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.